High rates of flares after anti‐tumor necrosis factor withdrawal in pediatric inflammatory bowel disease: A multi‐center study
Journal of Pediatric Gastroenterology and Nutrition · 17.11.2026
DOI: 10.1002/jpn3.70680 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, online erschienen am 17.11.2026. Verfasst von Maya Granot und 24 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Gastroenterology Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat-Gan, Tel-Aviv, Israel. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Research Council, Leona M. and Harry B. Helmsley Charitable Trust, ERC PoC.
Abstract (Originalsprache)
Objectives
Outcomes of anti‐tumor necrosis factor (anti‐TNF) discontinuation in pediatric patients with inflammatory bowel disease (IBD) remain unclear. We aimed to quantify relapse and biologic re‐initiation rates following anti‐TNF withdrawal in patients in sustained clinical remission for at least 6 months.
Methods
Patients' characteristics were recorded at the time of anti‐TNF discontinuation, at the time of flare, or at the end of follow‐up, with a minimum follow‐up of 1 year. A flare was defined as clinical, biochemical, or endoscopic activity leading to hospitalization, systemic corticosteroids, and/or initiation of a biologic.
Results
This multicenter retrospective study from the Pediatric IBD Porto Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) included 83 children from 21 centers (46 [55%] males, 59 Crohn's disease [CD], 24 ulcerative colitis [UC]), who discontinued anti‐TNF. At the time of anti‐TNF withdrawal, the median age was 14.8 years (interquartile range 12.4–16.9); 93% had biochemical remission, and 68% of those undergoing endoscopy were in endoscopic remission. Within 12 and 24 months, 45/83 (54%) and 56/74 (76%) experienced a flare, and 29/83 (35%) and 47/68 (69%) re‐initiated a biologic, respectively. Overall, flare and biologic re‐initiation rates were similar in CD and UC, between those with biochemical or endoscopic remission, and among those maintained on immunomodulators ( n = 33) or 5‐aminosalicylates ( n = 20). Univariate and multivariable Cox models did not identify baseline predictors of relapse or biologic re‐initiation.
Conclusions
Discontinuing anti‐TNF therapy in pediatric IBD patients in clinical remission is associated with high rates of disease flare and treatment re‐initiation. This provides quantitative data to help balance the benefits and risks when considering anti‐TNF withdrawal.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pediatric Gastroenterology Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat-Gan, Tel-Aviv, Israel.
- Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
- Department of Pediatric Gastroenterology, Sophia Children's Hospital, Erasmus MC, Rotterdam, the Netherlands.
- Department of Pediatric Gastroenterology, Hepatology and Nutrition, Royal Hospital for Children and Young People, Edinburgh, UK.
- Willem-Alexander Children's Hospital/Leiden University Medical Center, Leiden, the Netherlands.
- Pediatric Gastroenterology and Liver Unit, Maternal and Child Health Department, University Hospital-Umberto I, Sapienza University of Rome, Rome, Italy.
ORCID-Profile: Maya Granot, Anouk Camman, Saverio Pochesci, Lissy de Ridder, Salvatore Oliva, Patrizia Alvisi, Ben Kang, Ramit Magen Rimon, Kaija-Leena Kolho, Benedicte Pigneur, Dror S Shouval, Iva Hojsak, Paulina Krawiec, Laura Gianolio, Helena J Rolandsdotter, Firas Rinawi, Anat Yerushalmy-Feler, Marta Velasco Rodríguez-Belvís, Assaf Hoofien, Karl Mårild, Richard K Russell, Yael Haberman
Förderung
- European Research Council
- Leona M. and Harry B. Helmsley Charitable Trust
- ERC PoC
- Israel Science Foundation
- Tel Aviv University's Colton Center for Autoimmune Diseases
- Israel Science, Culture, and Sport
- LITWIN IBD PIONEERS AWARDS
- ESPGHAN (Maya Granot)
Zitieren
APA
Granot, M., Camman, A., Pochesci, S., de Ridder, L., Oliva, S., Alvisi, P., Kang, B., Magen Rimon, R., Kolho, K. L., Pigneur, B., Shouval, D. S., Hojsak, I., Krawiec, P., Strisciuglio, C., Gianolio, L., Kierkuś, J., Rolandsdotter, H. J., Rinawi, F., Yerushalmy-Feler, A., …, & Haberman, Y. (2026). High rates of flares after anti‐tumor necrosis factor withdrawal in pediatric inflammatory bowel disease: A multi‐center study. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.70680
Vancouver
Granot M, Camman A, Pochesci S, de Ridder L, Oliva S, Alvisi P, et al. High rates of flares after anti‐tumor necrosis factor withdrawal in pediatric inflammatory bowel disease: A multi‐center study. Journal of Pediatric Gastroenterology and Nutrition. 2026. doi:10.1002/jpn3.70680
BibTeX
@article{Granot2026,
author = {Granot, Maya and Camman, Anouk and Pochesci, Saverio and de Ridder, Lissy and Oliva, Salvatore and Alvisi, Patrizia and Kang, Ben and Magen Rimon, Ramit and Kolho, Kaija-Leena and Pigneur, Benedicte and Shouval, Dror S and Hojsak, Iva and Krawiec, Paulina and Strisciuglio, Caterina and Gianolio, Laura and Kierkuś, Jarosław and Rolandsdotter, Helena J and Rinawi, Firas and Yerushalmy-Feler, Anat and Velasco Rodríguez-Belvís, Marta and Hoofien, Assaf and Mårild, Karl and Weiss, Batia and Russell, Richard K and Haberman, Yael},
title = {High rates of flares after anti‐tumor necrosis factor withdrawal in pediatric inflammatory bowel disease: A multi‐center study},
journal = {Journal of Pediatric Gastroenterology and Nutrition},
year = {2026},
doi = {10.1002/jpn3.70680}
}
EUVIMED